VISA is a subtype of antimicrobial-resistant Staphylococcus aureus characterized by reduced susceptibility to vancomycin [1][3]. It represents a specific resistant phenotype within the broader S. aureus species [1].
Aperçu de la maladie
BactérienneInfection à Staphylococcus aureus intermédiaire à la Vancomycine
Vancomycin-intermediate Staphylococcus aureus infection
Suivre cette maladie Comparer les pays Informations étayées par des preuves EN 5/7 sections · FR 5/7 sections Mis à jour le Oct 23, 2026
Vancomycin-intermediate Staphylococcus aureus (VISA) is a rare antimicrobial-resistant form of S. aureus with reduced vancomycin susceptibility [1]. Its infections can present with skin, wound, bloodstream, or other staphylococcal disease manifestations [1][2][3]. Reported occurrence includes increasing incidence trends and elevated burden among bacteraemic patients [2][3].
Lire le profil clinique et épidémiologique complet 6
VISA infections resemble other staphylococcal illnesses and may appear as skin lesions, boils, wound infections, or bloodstream involvement [1][2][3]. Manifestations are clinically similar to methicillin-resistant S. aureus infections at sterile sites [2].
Vancomycin resistance in S. aureus is exceptionally rare overall [1]. A retrospective cohort identified 87 VISA sterile-site infections among 354 MRSA or VISA cases from 2009 to 2015, with no excess mortality versus non-VISA S. aureus [2]. A meta-analysis of MRSA isolates reported heterogeneous VISA prevalence around 6% globally, higher in bacteraemic patients (9.4%) than other infections (5.5%), with an increasing trend [3].
Resistant S. aureus can spread through close physical contact or contact with contaminated wound material, especially in healthcare environments [1]. Documented transmission of VRSA has not occurred in the U.S., but VISA may potentially spread by similar routes as MRSA [1].
Hand hygiene and adherence to core healthcare infection-control precautions, including glove use before and after contact with infectious substances, reduce spread [1]. Caregivers, visitors, and providers with close contact to hospital patients should follow these practices [1]. Avoiding contact with wounds or contaminated materials further limits transmission [1].
- 1 US Centers for Disease Control and Prevention. About Vancomycin-resistant Staphylococcus aureus | S. aureus | CDC [Internet]. cited 23 Oct 2026. Available from: https://www.cdc.gov/staphylococcus-aureus/about/vancomycin-resistant-staph.html
- 2 Burnham JP et al. Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. Antimicrob Agents Chemother. 2016 Sep. PMID: 27401565. doi: 10.1128/AAC.00925-16. PubMed: https://pubmed.ncbi.nlm.nih.gov/27401565/
- 3 Keikha M et al. Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997-2021): a systematic review and meta-analysis. J Glob Antimicrob Resist. 2024 Jun. PMID: 38336227. doi: 10.1016/j.jgar.2024.02.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/38336227/
Chargement des données actuelles…
Tendances nationales
Choisissez le pays, la source et la mesure ; chaque courbe conserve sa période et sa définition de déclaration.
Chargement des données…
Couverture des données
Pays et régions déclarants
La carte montre la couverture déclarée. Choisissez une mesure ou ouvrez un lieu coloré pour consulter ses données.
Chargement des données actuelles…
Profil de surveillance
Saisonnalité du pays sélectionné
Consultez les valeurs mensuelles d’un pays par année. Les cases vides indiquent une valeur non publiée.
Chargement des alertes officielles…
Téléchargement et méthodes
Choisissez une période et téléchargez les fichiers CSV, JSON ou XLSX.